Cryo Cell International (CCEL) Asset Writedowns and Impairment (2010 - 2026)

Cryo Cell International has disclosed Asset Writedowns and Impairment across 17 years of filings, most recently posting $213341.0 for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment fell 21.34% year-over-year to $213341.0; the TTM figure through Feb 2026 stood at $4.3 million (up 1380.81% YoY), while the FY2024 annual figure was $308000.0, down 64.55% from the prior year.
• Asset Writedowns and Impairment declined to $213341.0 in Q1 2026, from $4.4 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for CCEL reached as high as $4.4 million in Q4 2025 and fell as low as -$634405.0 in Q4 2022.
• The 5-year median for Asset Writedowns and Impairment is $225294.0 (2022), against an average of $666740.0.
• Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment jumped 1533.03% — and 2025, when it plunged 1509.6%.
• A 5-year view of Asset Writedowns and Impairment shows it stood at -$634405.0 in 2022, then jumped by 689.08% to $3.7 million in 2023, then tumbled by 99.49% to $19240.0 in 2024, then jumped by 22555.06% to $4.4 million in 2025, then sank by 95.11% to $213341.0 in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $213341.0, $4.4 million, and -$271207.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.